鲁抗医药：公司及控股子公司参与第十一批全国药品集中采购中选

Core Viewpoint - The announcement indicates that the company and its subsidiary have successfully won bids in the national centralized drug procurement, which is expected to contribute significantly to their revenue in the upcoming years [1] Group 1: Procurement Results - The company and its subsidiary, Shandong Lukang Pharmaceutical Group Set Co., Ltd., have been selected for the national centralized procurement of drugs [1] - The total sales revenue from the selected products for the year 2024 is projected to be 405 million yuan, accounting for approximately 6.49% of the company's total revenue for that year [1] - For the first half of 2025, the expected sales revenue from these products is 225 million yuan, representing about 7.14% of the company's revenue for that period [1]